Hexarelin (Examorelin) 2mg (price is per kit/10vials), 20mg
$209.94 If paid in BTC $167.95
Hexarelin (Examorelin) 20mg 2mg has to reconstituted with Bacteriostatic water (BAC).
2 mg per vial, 10 vials per 1 kit
Total amount of active ingredient: 20 mg Kit
Availability: In stock
Top Color: White
Shelf Life: 36 months
USA & CA : $39 (3-5 business days)
International : $45 (7-14 business days)
Enjoy these shipping rates for up to 10kits!
On the off chance that your shipment was seized (International Orders), we will give a half markdown pertinent on your next buy. Please contact us for more information.
Minimum Order: 1 kit (10 vials) / price is per kit
Hexarelin is a synthetic growth hormone secretagogue. It is derived from GHRP-6 and has effects similar to ghrelin. The primary function of hexarelin, as shown in animal research models, is to increase plasma levels of growth hormone and promote the development of lean body mass.
Indirectly, hexarelin has been shown to improve cardiac function, lower lipid levels, and protect against the effects of certain chemotherapeutic agents. The peptide is currently under investigation for its ability to mitigate the effects of certain metabolic diseases, such as diabetes.
What Does Hexarelin Do?
Like GHRP-6, hexarelin causes generous, portion subordinate increments in development hormone. Truth be told, hexarelin causes more significant increments in development hormone than normally emitted development hormone discharging hormone portion.
Not at all like GHRP-6, hexarelin doesn’t create considerable changes in prolactin, adrenocorticotropic hormone, or cortisol. It has no impact on glucose levels, luteinizing hormone, follicle invigorating hormone, or thyroid animating hormone.
Molecular Formula: C47H58N12O6
Molecular Mass: 887.04022
Amino Acid Sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys
Hexarelin Research Applications
There are a few dynamic territories of hexarelin investigate, with the most noticeable including metabolic conditions like diabetes. Hexarelin has recently been shown to activate CD36-PPARγ. PPARs (Peroxisome proliferator-activated receptors) are the target of many pharmaceuticals (e.g. thiazolidinediones) that improve insulin resistance. Improving insulin resistance helps lower blood sugar levels in type 2 diabetes and regulates lipid metabolism.
Closely linked to research in metabolic disease is research investigating the cardiac protective effects of hexarelin. The peptide can improve cardiac function in the setting of chronic heart failure, protect heart muscle following a heart attack, and reduce the formation of atherosclerotic plaques. Recently, studies designed to test the magnitude of hexarelin’s effect on the health of cardiomyocytes have revealed that the peptide is able to reduce scar formation following a heart attack. Truth be told, mice given hexarelin following heart ischemia show noteworthy improvement in a few cardiovascular parameters after only 14 days. Long-term remodeling is also favorably influenced, reducing the severity of the lifelong complications that often follow after a heart attack, .
Hexarelin Metabolic Research
The primary applications for hexarelin research effects on metabolism revolve around insulin resistance and lipid metabolism. Hexarelin has been appeared to considerably improve insulin opposition in diabetic rodents through the enactment of PPARγ and beta cells of the pancreas. Research has recommended that hexarelin not just improves the working of existing beta cells however causes the pancreas to recuperate and recover beta cells.
Lipid metabolism is the second area of metabolic research involving hexarelin. Abnormal lipid metabolism is an independent risk factor for diabetes. Even in non-obese individuals, abnormal lipid metabolism can lead to the development of type 2 diabetes. Studies in non-stout mice with useless fat digestion has uncovered that hexarelin essentially improves plasma glucose levels, which thusly decreases insulin discharge from the pancreas and long haul chance for the development of diabetes.
Hexarelin Cardiac Research
There is a lot of research concentrating on the cardiovascular impacts of hexarelin. The peptide has solid cardioprotective advantages, especially in instances of cardiovascular injury. Indeed, hexarelin has been appeared to restrain apoptosis following myocardial localized necrosis. This, thus, diminishes the measure of harm done to the heart (infarct size) temporarily. A decrease in momentary harm prompts a decrease in scar development and along these lines long haul confusions. Mice treated with hexarelin following cardiovascular ischemia exhibited improved discharge portion, decreased vascular obstruction, and improved results contrasted with controls. Additionally, hexarelin has been appeared to diminish atherosclerotic stores in courses, improving vascular wellbeing and decreasing the danger of coronary failure and stroke.
Hexarelin Protective Benefits
Hexarelin secures skeletal muscle in mouse models by forestalling apoptosis and muscle squandering. This is especially valid in models of muscle-squandering conditions (for example chemotherapy treatment). Research recommends that hexarelin secures muscle tissue by controlling calcium homeostasis. This impact is especially significant during scenes of muscle ischemia, in certain illness states, and during horrible injury to the muscle.
Hexarelin and Chemotherapy
As noted above, hexarelin ensures a few distinct kinds of muscle tissue, especially during ischemic or low-supplement states. Therefore, hexarelin has been of serious enthusiasm as a potential extra treatment for the disease. While there is some proof to demonstrate that hexarelin straightforwardly influences malignant growth cells, the essential enthusiasm among researchers is in the capacity of hexarelin to ensure muscle tissue against the damaging effects of chemotherapy. Heart harm, specifically, is a continuous symptom of chemotherapeutics, especially platinum-based medications. By restricting muscle squandering, hexarelin might be valuable in improving long haul endurance and even paces of abatement in malignant growth by permitting higher portions of in any case poisonous medications to be utilized.
Molecular formula: C47H58N12O6
Molar Mass: 887.04022
CAS number: 140703-51-1
All of our products are lab tested and the results are periodically published on the website.
Also known as: Hexarelin Acetate, HEX, Examorelin, L-Histidyl-2-methyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide
 L. Maréchal et al., “The CD36-PPARγ Pathway in Metabolic Disorders,” Int. J. Mol. Sci., vol. 19, no. 5, May 2018.
 R. M. H. Mosa, Z. Zhang, R. Shao, C. Deng, J. Chen, and C. Chen, “Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases,” Endocrine, vol. 49, no. 2, pp. 307–323, Jun. 2015.
 H. McDonald et al., “Hexarelin treatment preserves myocardial function and reduces cardiac fibrosis in a mouse model of acute myocardial infarction,” Physiol. Rep., vol. 6, no. 9, p. e13699, May 2018.
 X. Zhang, L. Qu, L. Chen, and C. Chen, “Improvement of cardiomyocyte function by in vivo hexarelin treatment in streptozotocin-induced diabetic rats,” Physiol. Rep., vol. 6, no. 4, Feb. 2018.
 M. Maccario et al., “Metabolic modulation of the growth hormone-releasing activity of hexarelin in man,” Metab. – Clin. Exp., vol. 44, no. 1, pp. 134–138, Jan. 1995.
 R. Mosa et al., “Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice,” Endocrinology, vol. 158, no. 10, pp. 3174–3187, Oct. 2017.
 Y. Mao, T. Tokudome, and I. Kishimoto, “The cardiovascular action of hexarelin,” J. Geriatr. Cardiol. JGC, vol. 11, no. 3, pp. 253–258, Sep. 2014.
 X. Xu et al., “Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat,” Am. J. Physiol. Heart Circ. Physiol., vol. 303, no. 6, pp. H703-711, Sep. 2012.
 Y. Ma, L. Zhang, B. S. Launikonis, and C. Chen, “Growth hormone secretagogues preserve the electrophysiological properties of mouse cardiomyocytes isolated from in vitro ischemia/reperfusion heart,” Endocrinology, vol. 153, no. 11, pp. 5480–5490, Nov. 2012.
 Y. Ma, L. Zhang, J. N. Edwards, B. S. Launikonis, and C. Chen, “Growth hormone secretagogues protect mouse cardiomyocytes from in vitro ischemia/reperfusion injury through regulation of intracellular calcium,” PloS One, vol. 7, no. 4, p. e35265, 2012.
 A. Liantonio et al., “Growth hormone secretagogues exert differential effects on skeletal muscle calcium homeostasis in male rats depending on the peptidyl/nonpeptidyl structure,” Endocrinology, vol. 154, no. 10, pp. 3764–3775, Oct. 2013.
 G. Sirago et al., “Growth hormone secretagogues hexarelin and JMV2894 protect skeletal muscle from mitochondrial damages in a rat model of cisplatin-induced cachexia,” Sci. Rep., vol. 7, no. 1, p. 13017, Oct. 2017.
Peptides are stable at room temperature and can be stored in their initial packaging for several days to weeks. Otherwise, peptides can be stored at 4 °C or below. Peptides should be protected from intense light.